# Lisa Bodei

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lisa-bodei/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,404 |
| Field | Neuroendocrine Tumor Research Advances |
| h-index | 72 |
| i10-index | 175 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5020320888 |
| ORCID iD | 0000-0001-6930-7383 |
| Works | 348 |

## Researcher papers

- [Radiopharmaceutical therapy in cancer: clinical advances and challenges](https://scholariq.org/papers/radiopharmaceutical-therapy-in-cancer-clinical-advances-and-challenges/)
- [The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours](https://scholariq.org/papers/the-joint-iaea-eanm-and-snmmi-practical-guidance-on-peptide-receptor/)
- [Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors](https://scholariq.org/papers/long-term-tolerability-of-prrt-in-807-patients-with-neuroendocrine-tumours-the/)
- [Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors](https://scholariq.org/papers/long-term-evaluation-of-renal-toxicity-after-peptide-receptor-radionuclide/)
- [Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study](https://scholariq.org/papers/peptide-receptor-radionuclide-therapy-with-177lu-dotatate-the-ieo-phase-i-ii/)
- [Radiotheranostics in oncology: current challenges and emerging opportunities](https://scholariq.org/papers/radiotheranostics-in-oncology-current-challenges-and-emerging-opportunities/)
- [EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)](https://scholariq.org/papers/eanm-procedure-guidelines-for-radionuclide-therapy-with-177lu-labelled-psma/)
- [Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.](https://scholariq.org/papers/overview-of-results-of-peptide-receptor-radionuclide-therapy-with-3-radiolabeled/)
- [ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues](https://scholariq.org/papers/enets-consensus-guidelines-for-the-standards-of-care-in-neuroendocrine-neoplasms/)
- [Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study](https://scholariq.org/papers/receptor-mediated-radionuclide-therapy-with-90y-dotatoc-in-association-with/)
- [Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update](https://scholariq.org/papers/systemic-therapy-in-patients-with-metastatic-castration-resistant-prostate/)

## Researcher topics

- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Medical Imaging Techniques and Applications](https://scholariq.org/topics/medical-imaging-techniques-and-applications/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.